PROTONIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROTONIX (PROTONIX).
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
| Metabolism | Extensively metabolized in the liver via CYP2C19 and CYP3A4. |
| Excretion | Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase. |
| Protein binding | ≥96% bound to albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd is approximately 11–23 L (0.2–0.5 L/kg), indicating distribution into extracellular fluid; low Vd consistent with high protein binding. |
| Bioavailability | Oral bioavailability is about 77% (tablet) but decreases to ≈50% when taken with food; IV bioavailability is 100%. |
| Onset of Action | Oral: Onset of antisecretory effect within 2.5 hours; peak acid suppression at 3–4 days. IV: Onset within 15–30 minutes with maximal effect at 2–3 hours. |
| Duration of Action | Duration of acid suppression lasts approximately 24 hours after a single dose, allowing once-daily dosing; therapeutic effect persists for several days after discontinuation due to irreversible pump inhibition. |
| Molecular Weight | 404.48 |
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
| Dosage form | FOR SUSPENSION, DELAYED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl >20 mL/min). For severe renal impairment (CrCl <20 mL/min), maximum dose is 40 mg/day; consider reducing dose to 20 mg/day. |
| Liver impairment | In patients with Child-Pugh Class A or B: no dose adjustment required. In Child-Pugh Class C: maximum dose is 40 mg/day; consider reducing dose to 20 mg/day. |
| Pediatric use | Children 1-16 years: weight-based dosing; 1.2 mg/kg/day orally (max 40 mg/day) for up to 8 weeks; for IV, no established pediatric dosing; use with caution. |
| Geriatric use | No specific dose adjustment required; however, consider lower starting dose (20 mg/day) due to decreased hepatic and renal function with age. |
| 1st trimester | No evidence of fetal harm in animal studies; limited human data. Use only if clearly needed. |
| 2nd trimester | No evidence of malformation risk; consider maternal benefit-risk. |
| 3rd trimester | May be used if clinically indicated; no known fetal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for PROTONIX (PROTONIX).
| Placental transfer | Crosses placenta in animal studies; human data limited but likely minimal transfer due to high protein binding. |
| Breastfeeding | Excreted into breast milk in low amounts; unlikely to cause adverse effects in infant. Consider benefit of therapy for mother and risk to infant. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to pantoprazole or any component of the formulation
| Precautions | Gastric malignancy risk (symptomatic response does not preclude malignancy), Acute interstitial nephritis, Cyanocobalamin (Vitamin B12) deficiency with long-term use, Hypomagnesemia, symptomatic and asymptomatic, especially with prolonged therapy, Clostridioides difficile-associated diarrhea (increased risk), Bone fracture risk (hip, wrist, spine) with high-dose or long-term use, Cutaneous and systemic lupus erythematosus, Fondaparinux interaction (increased bleeding risk) |
| Food/Dietary | Take on empty stomach at least 30 minutes before food; avoid high-fat meals which may delay absorption; no specific food prohibitions. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; first trimester: no increased risk of major malformations reported. Second and third trimesters: no documented fetal harm. However, use only if clearly needed. |
| Fetal Monitoring | Monitor maternal for potential adverse effects (e.g., Clostridium difficile infection, bone fracture risk). Fetal monitoring not specifically required; routine prenatal care. |
| Fertility Effects | No evidence of impaired fertility in animal studies. No human data; theoretical risk from hypergastrinemia and potential vitamin B12 deficiency with long-term use. |
| Clinical Pearls | For IV to oral conversion, use same dose; tablets can be dispersed in apple juice for administration via NG tube; do not crush or chew delayed-release tablets; avoid co-administration with clopidogrel due to reduced antiplatelet effect; monitor for hypomagnesemia with prolonged use. |
| Patient Advice | Take before the first meal of the day; swallow whole, do not crush or chew; antacids may be used if needed; report severe diarrhea or abdominal pain; avoid alcohol and NSAIDs to reduce gastric irritation. |